Multiplicity | Multiplicity | Count | % |
 SM post chemotherapy | Single | 7/13 | 53.8% |
Multiple | 3/13 | 23.1% | |
No | 3/13 | 23.1% | |
 DCE-MRI post chemotherapy | Single | 6/13 | 46.2% |
Multiple | 3/13 | 23.1% | |
No | 4/13 | 30.8% | |
 Postoperative pathology | Single | 3/13 | 23.1% |
Multiple | 3/13 | 23.1% | |
Lymph nodes | LN status | Count | % |
 SM post chemotherapy ALN | Pathological | 5/13 | 30.8% |
Non specific | 8/13 | 61.5% | |
 SM post chemotherapy other LNs | Non specific | 13/13 | 100.0% |
 DCE-MRI post chemotherapy ALN | pathological | 5/13 | 38.4% |
Non specific | 8/13 | 61.5% | |
 MRI Post chemotherapy other LNs | Non specific | 13/13 | 100.0% |
 DWI-MRI post chemotherapy ALN | pathological | 4/13 | 30.8% |
Non specific | 9/13 | 69.2% | |
 DWI-MRI post chemotherapy other LNs | Non specific | 13/13 | 100.0% |
 Postoperative pathology | pathological | 5/13 | 38.4% |
Non specific | 8/13 | 61.5% |